Hims & Hers Health, Inc. Expected to Earn Q4 2024 Earnings of $0.06 Per Share (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) – Leerink Partnrs upped their Q4 2024 earnings per share (EPS) estimates for shares of Hims & Hers Health in a research note issued on Monday, June 17th. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $0.06 per share for the quarter, up from their prior estimate of $0.03. Leerink Partnrs has a “Market Perform” rating on the stock. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.19 per share. Leerink Partnrs also issued estimates for Hims & Hers Health’s FY2025 earnings at $0.43 EPS, FY2026 earnings at $0.64 EPS and FY2027 earnings at $0.94 EPS.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. During the same period in the prior year, the firm posted ($0.05) EPS. Hims & Hers Health’s quarterly revenue was up 45.8% compared to the same quarter last year.

Several other equities research analysts have also weighed in on the company. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $20.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, May 22nd. Piper Sandler lifted their price objective on Hims & Hers Health from $11.00 to $13.00 and gave the stock a “neutral” rating in a report on Tuesday, May 7th. Imperial Capital raised Hims & Hers Health from an “in-line” rating to an “outperform” rating and set a $16.00 price objective for the company in a report on Wednesday, February 28th. Deutsche Bank Aktiengesellschaft lifted their price objective on Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a report on Tuesday, May 7th. Finally, Canaccord Genuity Group started coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $16.43.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $24.79 on Wednesday. Hims & Hers Health has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a market cap of $5.32 billion, a PE ratio of -2,479.00 and a beta of 1.08. The stock has a fifty day moving average price of $16.17 and a 200-day moving average price of $12.80.

Insider Activity

In other news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $14.97, for a total transaction of $2,827,653.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Soleil Boughton sold 2,503 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $15.65, for a total value of $39,171.95. Following the completion of the sale, the insider now owns 166,866 shares in the company, valued at approximately $2,611,452.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $14.97, for a total value of $2,827,653.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 880,687 shares of company stock worth $15,057,669. 17.71% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Hims & Hers Health

A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Hims & Hers Health by 1.0% during the first quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock valued at $221,379,000 after buying an additional 136,907 shares during the period. Forerunner Ventures Management LLC purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $86,836,000. Dimensional Fund Advisors LP increased its stake in shares of Hims & Hers Health by 9.9% during the fourth quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after buying an additional 193,507 shares during the period. Farallon Capital Management LLC increased its stake in shares of Hims & Hers Health by 3,890.5% during the first quarter. Farallon Capital Management LLC now owns 1,676,000 shares of the company’s stock valued at $25,928,000 after buying an additional 1,634,000 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Hims & Hers Health by 1.7% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock valued at $11,523,000 after buying an additional 22,009 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.